Apr 29 |
NKGen Biotech Announces FDA Clearance of Investigational New Drug (IND) Application for SNK01 NK Cell Therapy in Parkinson’s Disease
|
Apr 25 |
NKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
|
Apr 24 |
NKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Apr 18 |
NKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summit
|
Apr 11 |
NKGen Biotech rises 14% on receiving $5M funding for clinical programs
|
Apr 11 |
NKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programs
|
Mar 25 |
NKGen releases additional phase 1 data on Alzheimer's candidate
|
Mar 25 |
NKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer’s Disease at the Tau2024 Global Conference
|
Mar 4 |
NKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conference
|
Feb 7 |
Passage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companies
|